***Background.*** Relationships between antiretroviral (ART) adherence and virologic suppression are critical to understanding risk of treatment failure and drug resistance.

***Methods.*** We used objective monitors to collect adherence data on adults taking ART during 2005-2011. CD4 and viral load were collected quarterly. Our primary outcome was rebound HIV-1 RNA viremia, defined by a detectable viral load following a previously undetectable viral load (\<400 copies/mL). Our primary predictor was ART adherence, measured by: 1) average adherence, calculated by the number of pills taken divided by the number of pills prescribed; and 2) presence of three consecutive days of non-adherence. Secondary predictors were CD4 nadir and ART regimen. We used generalized estimating equations to fit regression models to assess for relationships between predictors and our outcome of interest.

***Results.*** 399 participants contributed 2,837 intervals during the follow-up. Median nadir CD4 was 125 and median duration of suppression was 1.1 years. The most common regimen was AZT/3TC/NVP, used by 58% of subjects. Risk of rebound viremia was higher during the first year of suppression than after in all adherence strata (3.5% vs 1.9% for average adherence \>90%, 5.3% vs 2.1% for average adherence 60-90%, and 14.2% vs 7.3% for average adherence \<60%, *P*\<0.06 for all categories). Compared to periods with average adherence \>90%, we found increased odds of rebound viremia for adherence \<60% during the first year (AOR = 6.0, *P* \<0.001) and after (AOR = 3.4 *P* =0.003); but increased odds for adherence 60-90% during the first year only (AOR = 1.9, *P* = 0.04 vs AOR = 0.8, *P* =0.60). One or more 72-hour gap was associated with increased odds of rebound viremia during the first year (AOR = 1.8, P = 0.05) and after (AOR = 2.2, P = 0.03). CD4 nadir was not predictive of rebound viremia, and there were no significant interactions in these relationships by regimen.

***Conclusion.*** In a cohort of PLWH on ART in rural Uganda, increasing duration of viral suppression was associated with reduced odds of viral rebound regardless of average adherence. Average adherence under 60% and one or more 72-hour treatment gaps are associated with increased risk of rebound viremia regardless of suppression time.
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